U.S. Develops a Vaccine to Treat Prostate

The BBC reported on the 20th that a research team consisting of scientists from around the world stated that they have adopted new methods to develop vaccines and used to treat prostate cancer. The report published in the journal Nature Medical magazine stated that DNA from healthy cells was used Develop new vaccines. This vaccine is used in mice with prostate cancer and the cure rate is as high as 80%.

The researchers believe that this method may be applicable to the development of other cancer vaccines, and have begun to study the melanoma vaccine.

The British Cancer Research Society stated that this is a heavy scientific research development, but the vaccine still needs human trials.

Developing a cancer vaccine is not a new initiative. Unlike the role of traditional vaccines in preventing disease, cancer vaccines achieve therapeutic effects by stimulating their own immune systems to attack already generated tumors.

The study conducted by the University of Leeds, UK, and a clinic in the United States, implanted the virus after decomposing DNA from healthy prostate cells.

This virus continues to infect test mice.

Prostate DNA makes this virus a prostatic antigen and learns to attack prostate cancer cells when the immune system resists the virus.

It is essential that healthy prostate cells and other body parts are not affected.

In the laboratory, scientists used only one course of nine injections to achieve an 80% cure rate for prostate tumors.

However, the researchers said that it will take many years for this vaccine to begin human trials.